Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial
Authors' conclusion
In Japanese adults with obesity and T2D, once-weekly treatment with tirzepatide (10 or 15 mg) demonstrated significant reductions in body weight compared with placebo, with the safety profile generally consistent with previous studies.
Study context
- Population
- Japanese adults with BMI ≥27 kg/m² and T2D with HbA1c ≥7% to ≤10%Japanese subpopulation
- Participants
- 41 adults
- Comparison
- Once-weekly tirzepatide 10 mg or 15 mg vs placebo, as adjunct to lifestyle interventions
- Primary endpoint
- Coprimary: mean percent change in body weight and proportion achieving ≥5% body weight reduction
- Follow-up
- Week 72
Methodological detailssubpopulation analysis, three clinical trial sites
- Subpopulation analysis
- Three clinical trial sites
Primary result
As reported in the abstract
Mean percent change in body weight from baseline
Tirzepatide 10 mg
−12.4
mean · SE 1.8% · %
Tirzepatide 15 mg
−10.2
mean · SE 1.8% · %
Placebo
−3.5
mean · SE 1.8% · %
Tirzepatide 10 mg vs Placebo: P = 0.001 · Tirzepatide 15 mg vs Placebo: P = 0.013
- Body weight reduction ≥5% (coprimary): tirzepatide 10 mg
- 85.7%
- Body weight reduction ≥5% (coprimary): tirzepatide 15 mg
- 78.6%
- Body weight reduction ≥5% (coprimary): placebo
- 46.2%
Further findings
- Reductions in glycemic parameters, waist circumference and systolic BP, and numerical improvements in lipid profile, with tirzepatide
Safety
- No new safety concerns were identified
Original publication
Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial. Diabetes Obes Metab. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →